SHIRE PLC (NASDAQ:SHPG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers Election of
Directors Appointment of Certain Officers Compensatory
Arrangements of Certain Officers.
The Board of Directors of Shire plc (Shire) announced on January
3, 2017 that Ian Clark will join the Board of Directors as a
non-executive director with effect from January 3, 2017. No
determination has been made as to any board committees on which
Mr. Clark may serve.
Mr. Clark will receive compensation in accordance with Shires
Remuneration Policy for non-executive directors. No shares will
be granted to Mr. Clark on his appointment as a director, but 25%
of the fees payable to him under the Remuneration Policy will be
payable in the form of shares.
Shire has issued a press release attached as Exhibit 99.1 which
is incorporated by reference herein.
Item 8.01. Other Events
Shire has issued a press release attached as Exhibit 99.2 which
is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits. The following exhibits are filed herewith:
99.1Press Release dated January 3, 2017
99.2Press Release dated January 4, 2017
About SHIRE PLC (NASDAQ:SHPG)
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase. SHIRE PLC (NASDAQ:SHPG) Recent Trading Information
SHIRE PLC (NASDAQ:SHPG) closed its last trading session up +2.00 at 181.74 with 999,310 shares trading hands.
